Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.

Future oncology (London, England) - 1 Feb 2013

Metro Giulio, Chiari Rita, Baldi Alice, De Angelis Verena, Minotti Vincenzo, Crinò Lucio

Abstract excerpt

Selumetinib is a potent and selective inhibitor of MEK1 and 2 that is currently being clinically developed for the treatment of several human malignancies. Initially administered as free-base suspension, a more convenient Hyd-sulfate capsule formulation has recently been developed. Phase I studies revealed that acneiform dermatitis was the dose-limiting toxicity of both the free-base and capsule formulation given...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Clinical Trials, Phase I as Topic

Share to Clinical Trials, Phase II as Topic

Share to Drug Evaluation, Preclinical

Share to Genes, ras

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 23414467
DOI: 10.2217/fon.12.198

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.PMID 23414467Read ↗

Selumetinib in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Selumetinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.Semantic proximity Read ↗

Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).Semantic proximity Read ↗

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.Semantic proximity Read ↗

Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.Semantic proximity Read ↗

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.Semantic proximity Read ↗

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.Semantic proximity Read ↗

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Semantic proximity Read ↗

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.Semantic proximity Read ↗

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Semantic proximity Read ↗

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.